Every material Form 8-K Drugs Made In America Acquisition II Corp. has filed with the SEC since March 17, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
A blank-check company disclosed two agreements dated April 22, 2026: an updated consulting statement of work for its CFO, Saleem Elmasri, and a compensation agreement for CEO Roger Bendelac. Both provide for ordinary share awards that are earned on signing a definitive business combination agreement and issued at closing of the initial business combination, which would dilute existing shareholders.
Updated statement of work with Titan Advisory Services LLC gives Elmasri 175,000 ordinary shares in place of the 100,000 shares in the original SoW, issued within ten days after closing of the initial business combination.
CEO compensation agreement with Aleutian Equity Holdings LLC sets Bendelac's pay at $4,500 per month, of which $2,500 is payable currently and up to $2,000 may be deferred.
Bendelac is also entitled to 250,000 ordinary shares, earned on execution of a definitive agreement and issued at closing of the initial business combination.
Deferred amounts accrue as binding obligations of the Company.
Drugs Made In America Acquisition II Corp. entered into a definitive agreement with Alpha Multi Family Office for a contemplated $1,400,000 convertible notes financing, following a $150,000 bridge loan issued March 11, 2026. The company also issued a $300,000 interim convertible note on March 30, 2026, which is a direct financial obligation and can convert into shares of the combined company after a business combination at a 35% discount to market.
Definitive Investment and Sponsor Transition Agreement effective March 24, 2026, for a contemplated $1,400,000 convertible notes financing
Interim Convertible Note of $300,000 issued March 30, 2026, with a maturity of nine months and no interest
Note converts after the initial business combination at a 35% discount to market price, at the investor's option
Proceeds to fund accounting, audit and other expenses related to the business combination
Drugs Made In America Acquisition II Corp. issued a $150,000 unsecured convertible bridge note to Alpha Multi Family Office on March 11, 2026, as the first payment toward a contemplated $1,400,000 convertible notes financing. The company intends to use the bridge proceeds for accounting, audit and other expenses related to its business combination, and the rest of the financing remains subject to a definitive agreement not yet signed.
Bridge note: $150,000 principal, no interest, maturity nine months from issuance, convertible at a 35% discount to market after a business combination
Total contemplated financing: $1,400,000, with $1,250,000 still subject to a convertible note purchase agreement yet to be negotiated
Addendum dated March 9, 2026 contemplates $400,000 in aggregate funding disbursed on or prior to March 30, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Drugs Made In America Acquisition II Corp. filing is on SEC EDGAR ↗. 8-K briefs of other companies →